Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers
- PMID: 27528622
- DOI: 10.1530/ERC-16-0277
Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers
Abstract
Pathogenic mutations in BRCA1 and BRCA2 are associated with high risks of breast and ovarian cancer. However, penetrance estimates for mutation carriers have been found to vary substantially between studies, and the observed differences in risk are consistent with the hypothesis that genetic and environmental factors modify cancer risks for women with these mutations. Direct evidence that this is the case has emerged in the past decade, through large-scale international collaborative efforts. Here, we describe the methodological challenges in the identification and characterisation of these risk-modifying factors, review the latest evidence on genetic and lifestyle/hormonal risk factors that modify breast and ovarian cancer risks for women with BRCA1 and BRCA2 mutations and outline the implications of these findings for cancer risk prediction. We also review the unresolved issues in this area of research and identify strategies of clinical implementation so that women with BRCA1 and BRCA2 mutations are no longer counselled on the basis of 'average' risk estimates.
Keywords: BRCA1; BRCA2; breast cancer; common genetic variants; genotype–phenotype; lifestyle/hormonal risk factors; modifier; ovarian cancer; risk prediction.
© 2016 Society for Endocrinology.
Similar articles
-
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.J Natl Cancer Inst. 2013 Jun 5;105(11):812-22. doi: 10.1093/jnci/djt095. Epub 2013 Apr 29. J Natl Cancer Inst. 2013. PMID: 23628597
-
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.Breast Cancer Res Treat. 2010 Dec;124(3):643-51. doi: 10.1007/s10549-010-0805-3. Epub 2010 Mar 4. Breast Cancer Res Treat. 2010. PMID: 20204502
-
Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2.Breast Cancer Res Treat. 2015 Aug;152(3):659-65. doi: 10.1007/s10549-015-3495-z. Epub 2015 Jul 21. Breast Cancer Res Treat. 2015. PMID: 26195121
-
Cancer risks among BRCA1 and BRCA2 mutation carriers.Br J Cancer. 2007 Jan 15;96(1):11-5. doi: 10.1038/sj.bjc.6603535. Br J Cancer. 2007. PMID: 17213823 Free PMC article. Review.
-
Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.Klin Onkol. 2019 Summer;32(Supplementum2):51-71. doi: 10.14735/amko2019S51. Klin Onkol. 2019. PMID: 31409081 Review. English.
Cited by
-
No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families.Genes (Basel). 2021 Jul 20;12(7):1100. doi: 10.3390/genes12071100. Genes (Basel). 2021. PMID: 34356116 Free PMC article.
-
Breast and ovarian cancer penetrance of BRCA1/2 mutations among Hong Kong women.Oncotarget. 2018 Feb 2;9(38):25025-25033. doi: 10.18632/oncotarget.24382. eCollection 2018 May 18. Oncotarget. 2018. PMID: 29861850 Free PMC article.
-
GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers.Front Oncol. 2018 Oct 31;8:490. doi: 10.3389/fonc.2018.00490. eCollection 2018. Front Oncol. 2018. PMID: 30430080 Free PMC article. No abstract available.
-
Key steps for effective breast cancer prevention.Nat Rev Cancer. 2020 Aug;20(8):417-436. doi: 10.1038/s41568-020-0266-x. Epub 2020 Jun 11. Nat Rev Cancer. 2020. PMID: 32528185 Review.
-
The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?Eur J Hum Genet. 2018 Jun;26(6):848-857. doi: 10.1038/s41431-018-0111-9. Epub 2018 Feb 26. Eur J Hum Genet. 2018. PMID: 29483665 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous